Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.
Cohen AD, Hari P, Htut M, Berdeja JG, Usmani SZ, Madduri D, Olyslager Y, Goldberg JD, Schecter JM, Jackson CC, Gries KS, Fastenau JM, Valluri S, Deraedt W, Akram M, Crawford R, Morrison R, Doward L, Morgan K, Seldam ST, Jakubowiak A, Jagannath S. Cohen AD, et al. Among authors: madduri d. Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):68-77. doi: 10.1016/j.clml.2022.10.001. Epub 2022 Oct 11. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36357295 Free article.
The effect of novel therapies in high-molecular-risk multiple myeloma.
Lancman G, Tremblay D, Barley K, Barlogie B, Cho HJ, Jagannath S, Madduri D, Moshier E, Parekh S, Chari A. Lancman G, et al. Among authors: madduri d. Clin Adv Hematol Oncol. 2017 Nov;15(11):870-879. Clin Adv Hematol Oncol. 2017. PMID: 29200420 Free PMC article. Review.
Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach.
Laganà A, Beno I, Melnekoff D, Leshchenko V, Madduri D, Ramdas D, Sanchez L, Niglio S, Perumal D, Kidd BA, Miotto R, Shaknovich R, Chari A, Cho HJ, Barlogie B, Jagannath S, Dudley JT, Parekh S. Laganà A, et al. Among authors: madduri d. JCO Precis Oncol. 2018;2018:PO.18.00019. doi: 10.1200/PO.18.00019. Epub 2018 Aug 8. JCO Precis Oncol. 2018. PMID: 30706044 Free PMC article.
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Raje N, et al. Among authors: madduri d. N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226. N Engl J Med. 2019. PMID: 31042825 Free PMC article. Clinical Trial.
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients.
Goldman-Mazur S, Jurczyszyn A, Castillo JJ, Waszczuk-Gajda A, Grząśko N, Radocha J, Bittrich M, Kortüm KM, Gozzetti A, Usnarska-Zubkiewicz L, Valls JD, Jayabalan DS, Niesvizky R, Kelman J, Coriu D, Rosiñol L, Szukalski Ł, González-Calle V, Mateos MV, Jamroziak K, Hus I, Avivi I, Cohen Y, Mazur P, Suska A, Chappell A, Madduri D, Chhabra S, Kleman A, Hari P, Delforge M, Robak P, Gentile M, Kozłowska I, Goldberg SL, Czepiel J, Długosz-Danecka M, Silbermann R, Olszewski AJ, Barth P, Mikala G, Chim CS, Vesole DH. Goldman-Mazur S, et al. Among authors: madduri d. Leuk Lymphoma. 2020 Aug;61(8):1885-1893. doi: 10.1080/10428194.2020.1749605. Epub 2020 Apr 19. Leuk Lymphoma. 2020. PMID: 32306794
Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra.
Jatiani SS, Aleman A, Madduri D, Chari A, Cho HJ, Richard S, Richter J, Brody J, Jagannath S, Parekh S. Jatiani SS, et al. Among authors: madduri d. Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):632-636.e1. doi: 10.1016/j.clml.2020.04.020. Epub 2020 May 11. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32553791 Free PMC article. No abstract available.
55 results